Addressing the 19th Scientific Retreat of the Prostate Cancer Foundation (PCF), Mike noted that the U.S. Food & Drug Administration has approved five new treatments for advanced prostate cancer in the past 30 months. Researchers and academic institutions for each of the five drugs – Provenge, Jevtana, Zytiga, Xgeva and Xtandi – received substantial early funding from the PCF, which has raised more than $500 million for prostate cancer research since 1993.